Melanoma, Cutaneous Malignant

Alternative Names

  • CMM
  • Melanoma, Malignant
  • Familial Atypical Mole-Malignant Melanoma Syndrome
  • FAMMM
  • Melanoma, Familial
  • MLM
  • Dysplastic Nevus Syndrome, Hereditary
  • DNS
  • Melanoma, Cutaneous Malignant, 1
  • CMM1
  • B-K Mole Syndrome
Back to search Result
WHO-ICD-10 version:2010

Neoplasms

Malignant neoplasms

OMIM Number

155600

Mode of Inheritance

Autosomal dominant

Gene Map Locus

1p22, 1p36,3p13,5p15,7q31,9p21,12q14,14q32,16q24.3,20q11

Description

Cutaneous Malignant Melanoma (CMM) is, as the name suggests, a cancer of melamin producing cells in the skin, which is responsible for 1-2% of all deaths related to cancer. CMM is also the eighth most common cancer in USA. Risk factors for the development of CMM include exposure to ultraviolet radiation, especially during childhood, white racial background, family history of melanoma, personal history of non-melanoma skin cancer, having atypical nevi or dysplastic nevi, or being born with giant melanocytic nevi. Four major types of CMM lesions identified are: superficial spreading melanoma, affecting both men and women equally, the aggressive nodular melanoma, affecting mostly men in their fifth decade of life, acral lentiginous melanoma, common in darkly pigmented individuals, and the rare desmoplastic melanoma, which shows a greater frequency of local recurrence, but is less likely to spread to lymph nodes.

The most common warning sign for CMM is a changing mole or blemish. The ABCD method is a useful diagnostic tool to identify CMM. The ABCD features used in characterizing the moles include any moles that are Asymmetric, have irregular Borders, show a recent change in Color, and are larger than 6mm in Diameter. Other symptoms may include pruritis, bleeding, itching, ulceration, or pain in a mole. Surgical management usually relies on excisional biopsy, where any suspected lesion is removed along with an ellipse of surrounding skin. In larger lesions, punch biopsy may be performed. Chemotherapy shows only a limited success. Of late, treatment with interleukin 2 has shown promise. Radiation therapy is often used following surgical management, and it may reduce the rate of local recurrence without prolonging survival. Advanced stages of the disease carry a median survival of 6 to 8 months after diagnosis.

As in most cancers, more than one genetic locus has been mapped for CMM. One such locus is the CDKN2A (Cyclin-Dependent Kinase Inhibitor 2A) gene on chromosome 9. Mutations in this gene affect the stability of the p53 tumor suppressor protein, which in turn stimulates the production of melanocyte stimulating hormone, resulting in melanocyte survival. Other loci identified include the CDK4 (Cyclin-Dependent Kinase 4), MITF (Melanocyte Inducing Transcription Factor) gene, TERT (Telomerase Reverse Transcriptase) gene, POT1 (Protection Of Telomeres 1) gene, MC1R (Melanocortin 1 Receptor) gene, and XRCC3 (X-Ray Repair Cross Complementing 3) gene.

Epidemiology in the Arab World

View Map

Other Reports

Jordan

Oumeish (1997) studied the epidemiologic aspects of cutaneous malignant melanoma among Jordanians. The clinical and the histopathologic feature of 138 melanoma patients (86 men, median age 56; 52 women, median age 53) seen during the period November 1969-May 1994 were studied. Malignant melanoma was found to be more common in men than women, in the ratio of approximately 2:1, due to the higher exposure of men to sunlight, and occurred more in people with skin types I, II, and III, and less in people with skin types IV and V. The majority of cases were of the superficial spreading variety, followed by the nodular, lentigo maligna, and acrolentiginous melanomas, respectively. Oumeish (1997) concluded that the incidence of cutaneous malignant melanoma, formerly considered a rare tumor in Jordan, is now recognized to be on the increase and that exposure to sunlight seems to be the most prominent risk factor in the development of this tumor among Jordanians.

Oman

Srinivasan et al. (1993) reported intracerebral metastasis in a patient who presented with malignant melanoma of the scalp. This 65-year old male presented with a circular lesion (1.5 cm in diameter) of the scalp in the fronto-parietal area of three weeks duration. The lesion was raised and ulcerated with slight pigmentation on the edges and bled on touch, but was not fixed to the calvarium. There was no history of a mole or trauma and there was no cervical lymphadenopathy on clinical examination. Skull and chest X-rays were normal with no periosteal or bone infiltration in the former study. A clinical diagnosis of granuloma pyogenicum was made and a differential diagnosis of melanoma was kept in mind. The histological report of the excision biopsy revealed malignant melanoma. On the fourth postoperative day, the patient developed right sided hemiplegia and CT scan of the brain revealed a large radiolucent space occupying lesion in the left parietal lobe which was removed via a left parietal craniotomy approach, after which the patient's neurological status improved. Histological examination showed metastatic malignant melanoma of the brain. Any micro-metastasis of the brain was dealt with by radiotherapy to the brain. Metastasis to other sites like the lung and liver were excluded by investigations. Since the patient had hematogenous spread to the brain with no lymphadenopathy, wide excision of the biopsy scar over the scalp and left radical neck dissection were not done. On follow up, eight months later the patient was having a normal life. Srinivasan et al. (1993) added that over a period of five years, they came across two cases with secondaries from melanoma (primary sites were foot and scalp). [Srinivasan V, Thomas C, Lad SD. Cutaneous malignant melanoma with metastatic intracerebral space occupying lesion. Oman Med J. 1993; 10(1):31-5.]

Pillai et al (1998) reported a primary amelanotic melanoma of the tongue in a 24-year old Omani male who presented with a one year's history of painless tongue swelling, which occasionally bled. He used to smoke two to three packets of cigarettes per day. This 0.75 cm swelling on the centre of the dorsum of the tongue was raised, firm, and had smooth surface. There was no regional lymphadenopathy. Investigations were normal. The swelling was surgically excised and histopathological examination showed brownish tissue (15x1x0.5 cm) with a whitish elevation on one side, with whitish and brownish areas on the cut surface. Microscopically, there was an area of ulceration with neoplasm beneath, composed of oval, polygonal, or spindle-shaped cells with eosinophilic cytoplasm, vesicular nuclei and prominent nucleoli. These cells were arranged in alveolar, sheets, or interlacing bundles infiltrating in between muscle fibers. The covering epithelium had pseudoepitheliomatous hyperplasia, and there were vascular emboli with no oral melanosis. Immunohistochemical staining revealed positivity for S-100 and Vimentin, but these cells were negative for keratin and desmin with occasional ones showing positivity for HMB-45. A diagnosis of amelanotic melanoma of the tongue was made according to the above findings. The wound healed without scar formation and after two months he was advised to undergo wider margin re-excision with suprahyoid node dissection. [Pillai R, Devi KRL, Sriganesh S, Pandit PN. Primary amelanotic melanoma of tongue, a case report. Oman Med J. 1998; 15(1):24-5.]

Sawardekar (2005) determined the prevalence of isolated minor congenital anomalies in 21988 births between 1993 and 2002 using data from the Nizwa Hospital register of congenital anomalies. A total of five children (three males and two females) with melanocytic nevi were born during this period, giving the condition a prevalence of 0.22 per 1000 births.

© CAGS 2024. All rights reserved.